Refractory Leukemia Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Refractory Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic LeukemiaLeukemiaRelapsed Leukemia+2 more
Jennifer R. Brown, MD, PhD64 enrolled1 locationNCT06644183
Recruiting
Phase 1Phase 2

A Study of Revumenib and Mezigdomide in People With Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+5 more
Memorial Sloan Kettering Cancer Center52 enrolled10 locationsNCT07356154
Recruiting
Phase 1

Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia

Relapsed LeukemiaRefractory Leukemia
Beijing 302 Hospital5 enrolled1 locationNCT07297173
Recruiting
Phase 2

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Leukemia, Myeloid, AcuteRefractory LeukemiaRelapsed Adult AML
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT05305859
Recruiting
Phase 2

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

Refractory Leukemia
Shanghai Jiao Tong University School of Medicine100 enrolled3 locationsNCT05870995
Recruiting

Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Chronic Lymphocytic LeukemiaRefractory LeukemiaRelapse Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto321 enrolled27 locationsNCT04282811
Recruiting
Early Phase 1

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Relapsed/refractory LymphomaRelapsed/Refractory Leukemia
Affiliated Hospital of Nantong University9 enrolled1 locationNCT06756321
Recruiting

Solving Riddles Through Sequencing

LeukemiaHematologic MalignancyUnknown Primary Tumors+3 more
Munich Leukemia Laboratory100 enrolled1 locationNCT05046444
Recruiting

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

Advanced LymphomaRefractory Acute Myeloid LeukemiaRefractory Lymphoma+2 more
Medical University of Vienna150 enrolled1 locationNCT04470947
Recruiting
Phase 1Phase 2

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid LeukemiaRefractory LeukemiaRelapse Leukemia+1 more
Chongqing Precision Biotech Co., Ltd36 enrolled1 locationNCT06006403
Recruiting
Phase 1

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

CARRefractory LeukemiaLymphoblastic Leukemia in Children+4 more
National University Hospital, Singapore20 enrolled1 locationNCT05043571